Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans - toxicological implications

被引:18
作者
Shindoh, Hidetoshi [1 ]
Nakano, Kohnosuke [1 ]
Yoshida, Takemi [2 ]
Ishigai, Masaki [1 ]
机构
[1] Chugai Pharmaceut Co Ltd, Kamakura Res Labs, Div Res, Preclin Res Dept, Kamakura, Kanagawa 2478530, Japan
[2] Showa Univ, Sch Pharm, Dept Biochem Toxicol, Shinagawa Ku, Tokyo 1428555, Japan
关键词
Capecitabine; 5 '-DFCR; 5 '-DFUR; 5-FU; Intestinal toxicity; METASTATIC COLORECTAL-CANCER; HUMAN LIVER; FLUOROPYRIMIDINE CARBAMATE; 5'-DEOXY-5-FLUOROCYTIDINE FORMATION; CYTIDINE DEAMINASE; PHASE-III; IRINOTECAN; DESIGN; ENZYME; TISSUE;
D O I
10.2131/jts.36.411
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Capecitabine is an oral anticancer prodrug which is converted to 5-fluorouracil (5-FU) via 3 enzymatic steps, these being 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and finally 5-FU by carboxylesterase (CES), cytidine deaminase (CDA), and thymidine phosphorylase (TP), respectively. Because rats, mice and monkeys are used for preclinical safety studies, we investigated the in vitro. conversion from capecitabine to 5-FU by hepatic and intestinal mucosal microsomes and cytosols, to compare their metabolic activity to that of humans. Capecitabine was hydrolyzed to 5'-DFCR in hepatic and intestinal mucosal microsomes in these animal species. In humans and monkeys, CLint (V-max/K-m) for the hydrolysis of capecitabine in intestine (expressed as mu l/min/g tissue) was much lower than that in hepatic microsomes but, in rats and mice, CLint was higher in intestine than in liver. In humans and monkeys, similar K-m values and inhibition patterns by tetrahydrouridine (THU) a CDA inhibitor, were observed in CDA activity of hepatic and intestinal cytosols. However, rats showed very low CDA activity and mice showed non-Michaelis-Menten kinetics and a different inhibition pattern by THU. K-m values for TP activity were almost similar in rats, mice, monkeys and humans. In conclusion, it was confirmed that monkeys are a suitable animal model for the safety assessment of capecitabine in terms of metabolic enzymes and it was suggested that higher toxic incidences in mouse small intestine were related to high hydrolytic activity of capecitabine in the small intestine.
引用
收藏
页码:411 / 422
页数:12
相关论文
共 25 条
  • [1] SELECTIVE-INHIBITION OF RAT-LIVER CARBOXYLESTERASES BY VARIOUS ORGANO-PHOSPHORUS DIESTERS INVIVO AND INVITRO
    BRANDT, E
    HEYMANN, E
    MENTLEIN, R
    [J]. BIOCHEMICAL PHARMACOLOGY, 1980, 29 (13) : 1927 - 1931
  • [2] STUDIES OF ENZYMATIC DEAMINATION OF CYTOSINE ARABINOSIDE .1. ENZYME DISTRIBUTION AND SPECIES SPECIFICITY
    CAMIENER, GW
    SMITH, CG
    [J]. BIOCHEMICAL PHARMACOLOGY, 1965, 14 (10) : 1405 - &
  • [3] Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Cassidy, Jim
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Saltz, Leonard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2006 - 2012
  • [4] PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS
    DAVIES, B
    MORRIS, T
    [J]. PHARMACEUTICAL RESEARCH, 1993, 10 (07) : 1093 - 1095
  • [5] Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
  • [6] Iwatsubo T, 1997, J PHARMACOL EXP THER, V283, P462
  • [7] Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile
    Mercier, Cedric
    Dupuis, Charlotte
    Blesius, Aurore
    Fanciullino, Raphaelle
    Yang, Chen Guang
    Padovani, Laetitia
    Giacometti, Sarah
    Frances, Nicolas
    Iliadis, Athanassios
    Duffaud, Florence
    Ciccolini, Joseph
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1177 - 1180
  • [8] Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
    Miwa, M
    Ura, M
    Nishida, M
    Sawada, N
    Ishikawa, T
    Mori, K
    Shimma, N
    Umeda, I
    Ishitsuka, H
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) : 1274 - 1281
  • [9] Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
    Moehler, Markus
    Sprinzl, Martin F.
    Abdelfattah, Murad
    Schimanski, Carl C.
    Adami, Bernd
    Godderz, Werner
    Majer, Klaus
    Flieger, Dimitri
    Teufel, Andreas
    Siebler, Juergen
    Hoehler, Thomas
    Galle, Peter R.
    Kanzler, Stephan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (04) : 449 - 456
  • [10] ONODERA H, 2000, XENOBIO METABOL DISP, V15, P439